HCRN GU16-260
Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Status: Closed to Accrual
Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Status: Closed to Accrual
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)
Status: Closed to Accrual
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
Status: Closed to Accrual
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter